Immatics N.V. (NASDAQ:IMTX) Receives $19.00 Average PT from Analysts

Shares of Immatics N.V. (NASDAQ:IMTX) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $19.00.

IMTX has been the subject of a number of recent research reports. Jefferies Financial Group began coverage on Immatics in a research report on Monday, March 16th. They set a “buy” rating and a $18.00 price objective for the company. Leerink Partners reaffirmed an “outperform” rating and set a $17.00 price target on shares of Immatics in a research note on Thursday, December 4th. Mizuho set a $25.00 price target on shares of Immatics in a report on Thursday, February 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immatics in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Immatics from a “sell” rating to a “hold” rating in a research note on Monday, March 9th.

Immatics Stock Performance

Shares of NASDAQ:IMTX opened at $9.77 on Tuesday. The business’s fifty day moving average price is $9.85 and its two-hundred day moving average price is $9.58. The stock has a market cap of $1.31 billion, a PE ratio of -5.31 and a beta of 1.34. Immatics has a one year low of $3.30 and a one year high of $12.41.

Immatics (NASDAQ:IMTX) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.14. Immatics had a negative return on equity of 41.81% and a negative net margin of 411.90%.The company had revenue of $23.00 million during the quarter, compared to analysts’ expectations of $12.18 million. As a group, equities research analysts predict that Immatics will post -0.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Bank of America Corp DE boosted its holdings in shares of Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after purchasing an additional 2,231 shares during the last quarter. Quarry LP acquired a new position in Immatics in the fourth quarter valued at $84,000. Insigneo Advisory Services LLC acquired a new position in Immatics in the third quarter valued at $103,000. Fox Run Management L.L.C. purchased a new position in Immatics during the fourth quarter worth about $129,000. Finally, Graham Capital Management L.P. purchased a new position in Immatics during the fourth quarter worth about $206,000. Hedge funds and other institutional investors own 64.41% of the company’s stock.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.